The idea of transforming a spinal disc into connective tissue in order to cure discogenic chronic low back pain came to Kjell Olmarker while waiting for a delayed flight. The idea became the basis for Stayble Therapeutics and the injectable drug STA363. The company is now conducting a phase IIb study that follows upon successful phase Ib results. BioStock has spoken with the company’s CEO Andreas Gerward about the treatment, the ongoing study, and the company’s future prospects.
Read the full article at biostock.se:
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se